Patents by Inventor Peter Nussbaumer
Peter Nussbaumer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220370440Abstract: The present invention relates to certain 4-substituted 1H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds is useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of ErbB receptor, especially of Exon20 Her2 and EGFR mutations.Type: ApplicationFiled: August 23, 2019Publication date: November 24, 2022Inventors: Carsten Schultz-Fademrecht, Bert Klebl, Peter Nussbaumer, Carsten Degenhart, Matthias Baumann
-
Publication number: 20220169616Abstract: The present invention relates to compounds of the general formula (I): (I), wherein V, W, M, R, R and Y have the designations cited below, or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof, and to processes for the preparation of compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof. The invention also relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for use as a medicament. Further, the invention relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for use in the treatment of cancer. Moreover, the invention relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for treating cancer in simultaneous, alternating or subsequent combination with another cancer therapy.Type: ApplicationFiled: March 19, 2020Publication date: June 2, 2022Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Peter Schröder
-
Patent number: 11111238Abstract: The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.Type: GrantFiled: September 20, 2018Date of Patent: September 7, 2021Assignees: Lead Discovery Center GmbH, Max Planck Gesellschaft zur Förderung der Wissenschften e.V., SOTIO a.s.Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
-
Publication number: 20210198269Abstract: The present invention relates to 2,6-methanobenzo[g][l]oxacin-4-onecompounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][l]oxacin-4-one compounds and their analog compounds.Type: ApplicationFiled: September 5, 2019Publication date: July 1, 2021Inventors: Herbert Waldmann, Gunther Zischinsky, Peter Nussbaumer, Slava Ziegler, Melanie Schwalfenberg, Javier de Ceballos Cerrajeria, Elena Sabrina Reckzeh, George Karageorgis
-
Publication number: 20200291011Abstract: The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.Type: ApplicationFiled: September 20, 2018Publication date: September 17, 2020Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
-
Patent number: 10703735Abstract: The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.Type: GrantFiled: July 23, 2019Date of Patent: July 7, 2020Assignees: Lead Discovery Center GmbH, Max Planck Gesellschaft zur Förderung der Wissenschaften e. V.Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
-
Publication number: 20200031794Abstract: The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.Type: ApplicationFiled: July 23, 2019Publication date: January 30, 2020Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
-
Patent number: 9453051Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.Type: GrantFiled: August 29, 2012Date of Patent: September 27, 2016Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Lead Discovery Center GmbHInventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
-
Patent number: 9242937Abstract: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.Type: GrantFiled: March 1, 2012Date of Patent: January 26, 2016Assignees: Bayer Intellectual Property GmbH, LEAD DISCOVERY CENTER GMBHInventors: Gerd Rühter, Peter Nussbaumer, Axel Choidas, Carsten Schulz-Fademrecht, Bert Klebl, Jan Eickhoff
-
Patent number: 9226929Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.Type: GrantFiled: March 1, 2012Date of Patent: January 5, 2016Assignee: Bayer Intellectual Property GMBHInventors: Gerd Rühter, Uwe Koch, Peter Nussbaumer, Carsten Schulz-Fademrecht, Jan Eickhoff
-
Patent number: 9096608Abstract: Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.Type: GrantFiled: March 1, 2013Date of Patent: August 4, 2015Assignee: Lead Discovery Center GmbHInventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch, Gerd Rühter, Carsten Schultz-Fademrecht, Peter Nussbaumer
-
Publication number: 20150111873Abstract: Pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives as inhibitors for a protein kinase.Type: ApplicationFiled: March 1, 2013Publication date: April 23, 2015Applicant: LEAD DISCOVERY CENTER GMBHInventors: Jan Eickhoff, Gunther Zischinsky, Uwe Koch, Gerd Rühter, Carsten Schultz-Fademrecht, Peter Nussbaumer
-
Publication number: 20140316104Abstract: The present invention relates to novel cyclosporin derivatives that do not cross the cellular membrane. The compounds according to the invention are used in medicine, more particularly in the treatment/diagnosis of acute and chronic inflammatory diseases, viral infections, cancer, degenerative muscle diseases, neurodegenerative diseases and damage that is associated with calcium homeostasis impairment. The novel cyclosporin derivatives additionally have no immunosuppressive effect.Type: ApplicationFiled: August 29, 2012Publication date: October 23, 2014Applicants: LEAD DISCOVER CENTER GMBH, MAX-PLANCK-GUSELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.Inventors: Gunter Fischer, Miroslav Malesevic, Frank Erdmann, Jan Kuhling, Michael Bukrinsky, Stephanie Constant, Gerd Ruhter, Peter Nussbaumer, Klaus Dinkel
-
Publication number: 20140296304Abstract: The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase.Type: ApplicationFiled: March 1, 2012Publication date: October 2, 2014Applicants: LEAD DISCOVERY CENTER GMBH, BAYER INTELLECTUAL PROPERTY GMBHInventors: Gerd Rühter, Peter Nussbaumer, Axel Choidas, Carsten Schulz-Fademrecht, Bert Klebl, Jan Eickhoff
-
Publication number: 20140179662Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.Type: ApplicationFiled: March 1, 2012Publication date: June 26, 2014Applicants: LEAD DISCOVERY CENTER GMBH, BAYER INTELLECTUAL PROPERTY GMBHInventors: Gerd Rühter, Uwe Koch, Peter Nussbaumer, Carsten Schulz-Fademrecht, Jan Eickhoff
-
Publication number: 20130079345Abstract: The present invention relates to disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted triazine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted triazine derivatives as inhibitors for a protein kinase.Type: ApplicationFiled: March 20, 2011Publication date: March 28, 2013Applicants: BAYER INTELLECTUAL PROPERTY GMBH, LEAD DISCOVERY CENTER GMBHInventors: Jan Eickhoff, Peter Nussbaumer, Gerd Ruhter, Carsten Schultz-Fademrecht, Ulrich Lucking, Axel Choidas, Bert Klebl
-
Patent number: 7928093Abstract: A compound of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.Type: GrantFiled: May 25, 2005Date of Patent: April 19, 2011Assignee: Novartis AGInventors: Klaus Hinterding, Klemens Högenauer, Peter Nussbaumer
-
Patent number: 7825260Abstract: Compounds of formula I, wherein X, a, b, R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.Type: GrantFiled: April 29, 2004Date of Patent: November 2, 2010Assignee: Novartis AGInventors: Rainer Albert, Claus Ehrhardt, Peter Ettmayer, Klaus Hinterding, Klemens Högenauer, Peter Nussbaumer
-
Patent number: 7482462Abstract: A compound of formula wherein R1 is haloalkyl, alkenyl, phenyl, thienyl, pyridine, benzthiazolyl, chromanyl (1,2-dihydrobenzopyranyl) or (C6-18)aryl, and R1 or R2 independently of each other are substituted (C4-8)cycloalkyl, a substituted bridged cycloalkyl system, substituted piperidine, substituted tetrahydropyridine, or a substituted bridged heterocyclic system, useful as a pharmaceutical.Type: GrantFiled: October 4, 2002Date of Patent: January 27, 2009Inventors: Amarylla Horvath, Philipp Lehr, Peter Nussbaumer, Erwin Paul Schreiner
-
Publication number: 20080318255Abstract: The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.Type: ApplicationFiled: September 28, 2004Publication date: December 25, 2008Inventors: Andreas Billich, Peter Ettmayer, Diana Mechtcheriakova, Peter Nussbaumer, Alexander Wlachos